drugset / Trial / NCT03490097
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to determine if statin can affect the clinical outcome of chronic hepatitis C patients receiving Sofosbuvir/Daclatasvir/Ribavirin combination
Timeline
- Start
- 2017-12-01
- Primary completion
- 2018-05-23
- Completion
- 2018-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclatasvir | Small molecule | 60 mg | — |
| Subject | Simvastatin | Small molecule | 10 mg | — |
| Subject | Sofosbuvir | Small molecule | 400 mg | — |